|
|
Volumn 5, Issue 7, 2010, Pages 1163-1164
|
|
Anemia therapy in ESRD: Time to move on
a
b
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HEMOGLOBIN;
IRON;
RECOMBINANT ERYTHROPOIETIN;
ANTIANEMIC AGENT;
BIOLOGICAL MARKER;
ANEMIA;
BLOOD TRANSFUSION;
CHRONIC KIDNEY DISEASE;
COST OF ILLNESS;
EDITORIAL;
HEMOGLOBIN BLOOD LEVEL;
HUMAN;
KIDNEY FAILURE;
PROFIT;
SURVIVAL;
TREATMENT OUTCOME;
UREMIA;
BLOOD;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASES;
COMPLICATION;
DRUG EFFECTS;
ERYTHROPOIESIS;
EVIDENCE BASED MEDICINE;
KIDNEY FAILURE, CHRONIC;
METABOLISM;
MORTALITY;
PATHOPHYSIOLOGY;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PRACTICE GUIDELINE;
RISK ASSESSMENT;
RISK FACTOR;
ANEMIA;
BIOLOGICAL MARKERS;
BLOOD PRESSURE;
BLOOD TRANSFUSION;
CARDIOVASCULAR DISEASES;
ERYTHROPOIESIS;
EVIDENCE-BASED MEDICINE;
HEMATINICS;
HEMOGLOBINS;
HUMANS;
INDIVIDUALIZED MEDICINE;
KIDNEY FAILURE, CHRONIC;
PATIENT SELECTION;
PRACTICE GUIDELINES AS TOPIC;
RISK ASSESSMENT;
RISK FACTORS;
|
|
EID: 77954793929
PISSN: 15559041
EISSN: 1555905X
Source Type: Journal
DOI: 10.2215/CJN.03680410 Document Type: Editorial |
|
Times cited : (2)
|
|
References (4)
|
